Concerto HealthAI and Pfizer to develop new study designs using real-world evidence and AI for various cancers

Written by Ilana Landau, Editor

Concerto HealthAI (MA, USA) and Pfizer (NY, USA) have announced the expansion of their existing collaboration, with the aim of developing new study designs for various cancers by employing real-world evidence and artificial intelligence (AI). Concerto HealthAI (MA, USA) and Pfizer (NY, USA) have jointly announced the expansion of their existing precision oncology collaboration, with the aim of advancing use of real-world evidence and artificial intelligence (AI) for breast, lung, prostate and renal cell carcinoma cancers, to provide novel study designs and non-interventional studies. The original collaboration, first announced in April 2019, saw Concerto HealthAI and Pfizer partner to make use...

To view the full article, please register now for access

It's completely free